Omeros (OMER) Prices $50M Upsized Share Offering at $13.10/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
After-Hours Movers 12/04: (SEAC) (VRNT) (TLYS) Higher; (HOME) (ESTC) (OMER) Lower (more...)
December 4, 2019 5:51 PM ESTAfter-Horus Movers
At Home Group (NYSE: HOME) 39.8% LOWER; reported Q3 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $318.7 million versus the consensus estimate of $314.86 million. At Home Group sees FY2020 EPS of $0.51-$0.56, versus the consensus of $0.68. At Home Group sees FY2020 revenue of $1.352-1.36 billion, versus the consensus of $1.38 billion. Comp store sales (2.6)% to (2.0)%
SeaChange Int'l (NASDAQ: SEAC) 14.9% HIGHER; reported Q3 EPS of $0.14, versus ($0.01) reported last year. Revenue for... More
Omeros (OMER) to Offer Common Stock
December 4, 2019 4:14 PM ESTOmeros Corporation (Nasdaq: OMER) announced that it has commenced a registered underwritten public offering of its common stock. In addition, Omeros has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in... More
Omeros (OMER) Reports Positive Data Across Primary and Secondary Endpoints in Pivotal Trial of HSCT-TMA Patients Treated with Narsoplimab
December 4, 2019 7:05 AM ESTOmeros Corporation (Nasdaq: OMER) today announced positive data from its pivotal clinical trial of the companys novel investigational complement inhibitor narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a frequently lethal complication of HSCT. These preliminary data were recently provided to FDA as part of the companys ongoing interactions with the Agency on the narsoplimab Biologics License Application (BLA). All safety and efficacy endpoints including the composite primary endpoint and the secondary endpoints are agreed with FDA. The reported data support a strongly positive benefit-risk balance.
The primary... More
